

Attorney Docket No.: RTS-0343
Inventors: Cowser and Freier
Serial No.: 10/023,782
Filing Date: December 17, 2001
Page 2

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of the Claims:

Claim 1 (currently amended): A compound 8 to 50 nucleobases in length targeted to nucleobases 1529 through 2087 of a 3'-untranslated region of a nucleic acid molecule encoding TFAP2C (SEQ ID NO: 3), wherein said compound specifically hybridizes with said nucleic acid molecule encoding TFAP2C and inhibits the expression of TFAP2C.

Claim 2 (original): The compound of claim 1 which is an antisense oligonucleotide.

Claim 3 (canceled):

Claim 4 (original): The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.

Claim 5 (original): The compound of claim 4 wherein the modified internucleoside linkage is a phosphorothioate linkage.

Claim 6 (original): The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.

Attorney Docket No.: RTS-0343
Inventors: Cowser and Freier
Serial No.: 10/023,782
Filing Date: December 17, 2001
Page 3

Claim 7 (original): The compound of claim 6 wherein the modified sugar moiety is a 2'-o-methoxyethyl sugar moiety.

Claim 8 (original): The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.

Claim 9 (original): The compound of claim 8 wherein the modified nucleobase is a 5-methylcytosine.

Claim 10 (original): The compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide.

Claim 11 (canceled).

Claim 12 (original): A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

Claim 13 (original): The composition of claim 12 further comprising a colloidal dispersion system.

Claim 14 (original): The composition of claim 12 wherein the compound is an antisense oligonucleotide.

Claim 15 (withdrawn): A method of inhibiting the expression of TFAP2C in cells or tissues comprising contacting said cells or tissues with the compound of claim 1 so that expression of TFAP2C is inhibited.

Attorney Docket No.: RTS-0343
Inventors: Cowser and Freier
Serial No.: 10/023,782
Filing Date: December 17, 2001
Page 4

Claim 16 (withdrawn): A method of treating an animal having a disease or condition associated with TFAP2C comprising administering to said animal a therapeutically or prophylactically effective amount of the compound of claim 1 so that expression of TFAP2C is inhibited.

Claim 17 (withdrawn): The method of claim 16 wherein the disease or condition is a hyperproliferative disorder.

Claim 18 (withdrawn): The method of claim 17 wherein the hyperproliferative disorder is cancer.

Claim 19 (withdrawn): The method of claim 18 wherein the cancer is selected from the group consisting of breast cancer and colon cancer.

Claim 20 (withdrawn): The method of claim 16 wherein the disease or condition is a developmental disorder.